Stablepoint Partners’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.64M Buy
67,206
+537
+0.8% +$62.9K 1.2% 20
2026
Q1
$8.02M Sell
66,669
-4,768
-7% -$550K 1.19% 21
2025
Q4
$7.52M Buy
71,437
+808
+1% +$75.8K 1.17% 19
2025
Q3
$5.93M Buy
70,629
+9,260
+15% +$763K 0.94% 36
2025
Q2
$4.86M Buy
61,369
+931
+2% +$74K 0.83% 43
2025
Q1
$5.42M Buy
60,438
+9,815
+19% +$916K 0.98% 32
2024
Q4
$5.04M Buy
50,623
+1,181
+2% +$122K 0.92% 32
2024
Q3
$5.61M Buy
49,442
+552
+1% +$65.6K 1.02% 29
2024
Q2
$6.25M Sell
48,890
-1,166
-2% -$150K 1.21% 17
2024
Q1
$6.6M Buy
50,056
+6,644
+15% +$819K 1.34% 11
2023
Q4
$4.73M Buy
+43,412
New +$4.51M 1.21% 21

Other funds holding MRK

Stablepoint Partners's MRK Position: Q2 2026 in Review

Stablepoint Partners increased its Merck (MRK) stake by 0.81% in Q2 2026, buying an estimated $62.9K and bringing the position to 67,206 shares worth $8.64M. The position accounts for 1.2% of the portfolio, ranked #20.

Stablepoint Partners first reported a position in MRK in Q4 2023 and has held it in 11 quarters since. 1,635 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Stablepoint Partners held 67,206 shares of Merck worth $8.64M as of Q2 2026.
  • Stablepoint Partners bought 537 Merck shares in Q2 2026, an estimated $62.9K.
  • Merck made up 1.2% of Stablepoint Partners's portfolio in Q2 2026, its #20 holding.
  • Stablepoint Partners first reported a position in Merck in Q4 2023 and has held it in 11 quarters since.
  • 1,635 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Stablepoint Partners's 13F filing for Q2 2026, filed 9 Jul 2026.